MedTrace Logo

Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer

NCT06706973 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-11-27

No results posted yet for this study

Summary

Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and feasible option to build upon. Our overarching hypothesis is that unique histone marks distinguish HPV+ and HPV- HNC and that specific histone modifiers are novel mediators of HNC tumorigenesis in an HPV specific manner

Conditions

Sponsors & Collaborators

  • AIRC (Italian Association for Cancer Research)

    collaborator UNKNOWN

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Susanna Chiocca · Istituto Europeo di Oncologia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-06
Primary Completion
2030-04-04
Completion
2030-04-04

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06706973 on ClinicalTrials.gov